Xilio Therapeutics Inc (XLO) Stock Price, Quote & News

Company Profile

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 524 2466

Website: xiliotx.com

Address:

828 Winter Street, Suite 300, Waltham, United States

809trader Jul. 4 at 11:48 AM

$XLO out of the 6+ million shares outstanding only 3.8 millions are available to trade. Out of that 3.8 millions only 1.4 million shares are held by retail investor. Think about that. 1.3 million shares. Any partnership announcement or good milestone payment will send this piggy flying. Now I see why they didn’t PR AbbVie $6 million milestone payment. They knew they can’t hold the stock down. My senses are saying we are getting a PR very soon. HAPPY 250th BIRTHDAY AMERICA !!! ❤️🇺🇸

0 · Reply

biohuntress Jun. 30 at 6:50 PM

$XLO I've become wary of the CEO's enthusiasm but she mentioned XLO wanted to carve out a clause that reserves the right to pair Vilastobart with XLO drugs.....that sounds like they were in partnership discussions pending the just completed Vilastobart trial....it's strange how Vilastobart has gone off the radar....partnership would be a nice surprise

2 · Reply

LabPsycho Jun. 30 at 6:03 PM

$XLO 1. Low float + 2. Trading at a fraction of cash! 3. Trading at an even smaller fraction of potentially more cash from partners later this year 4. Gilead, Abbvie, Roche partners

0 · Reply

LabPsycho Jun. 30 at 5:58 PM

$XLO Updated presentation out yesterday https://ir.xiliotx.com/static-files/0858e9cf-fd93-4938-8f02-396e622e8edf

1 · Reply

LabPsycho Jun. 30 at 2:54 PM

$XLO Look at the newcomers / posters below...looks like part of the PrePump gang moving in to help run this up to $19 or so soon?

2 · Reply

FutureScout Jun. 30 at 1:31 PM

$XLO is currently priced at $9.27.THE core narrative for the company involves the progress of its masked platform technology. With a planned IND submission for XTX501 in mid-2026 and Phase 1 initiation later this year, the company is preparing for significant clinical catalysts.The presence of major pharmaceutical shareholders continues to provide a foundation for market interest.

1 · Reply

AlphaVisionn Jun. 30 at 1:30 PM

$XLO is currently trading at $9.27.THE company is advancing its clinical pipeline, with plans for an IND submission in mid-2026.Focus remains on the development of XTX501, a bispecific PD-1 and masked IL-2 candidate. Market interest is supported by a stable shareholder base involving major pharmaceutical partners.

0 · Reply

809trader Jun. 30 at 12:50 PM

$XLO have a least 2 milestone that were supposed happen in the first half/second quarter. Today is the last day.

0 · Reply

TopSarge Jun. 29 at 6:12 PM

$XLO This one has momentum potential

1 · Reply

Jtlo Jun. 29 at 4:38 PM

$XLO come on 20

0 · Reply

Xilio Therapeutics appoints Ben Harshbarger as chief legal officer

Jun 29, 2026, 7:30 AM EDT - 5 days ago

Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer

May 27, 2026, 8:00 AM EDT - 5 weeks ago

Xilio Therapeutics Registration statement: Registration filing

2026-05-12T16:42:54.000Z - 7 weeks ago

Xilio Therapeutics files $250M mixed securities shelf

May 12, 2026, 8:00 AM EDT - 7 weeks ago

Xilio Therapeutics Registration statement: Registration filing

May 12, 2026, 7:30 AM EDT - 7 weeks ago

Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates

May 12, 2026, 7:30 AM EDT - 7 weeks ago

Xilio Therapeutics Earnings release: Q1 2026

May 12, 2026, 7:30 AM EDT - 7 weeks ago

Xilio Therapeutics Quarterly report: Q1 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Xilio Therapeutics Proxy statement: Proxy filing

2026-04-17T20:20:14.000Z - 2 months ago

Xilio announces new preclinical data for XTX601 at AACR

Apr 17, 2026, 4:01 PM EDT - 2 months ago

Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2

2026-04-16T11:40:39.000Z - 2 months ago

Xilio Therapeutics appoints Blanchard to its Board of Directors

Apr 16, 2026, 7:30 AM EDT - 2 months ago

Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D.

Mar 23, 2026, 7:30 AM EDT - 3 months ago

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results

Mar 23, 2026, 7:30 AM EDT - 3 months ago

Xilio Therapeutics Annual report: Q4 2025

Mar 23, 2026, 7:30 AM EDT - 3 months ago

Xilio Therapeutics Earnings release: Q4 2025

Mar 23, 2026, 7:30 AM EDT - 3 months ago

Xilio Therapeutics Annual report: Q4 2025

Mar 17, 2026, 4:45 PM EDT - 3 months ago

Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting

2026-03-13T23:52:06.000Z - 4 months ago

Xilio Therapeutics Inc trading halted, news pending

2026-03-12T12:45:03.000Z - 4 months ago

Xilio Therapeutics announces 1-for-14 reverse stock split

Mar 12, 2026, 8:30 AM EDT - 4 months ago

Xilio Therapeutics Announces 1-for-14 Reverse Stock Split

Mar 9, 2026, 3:00 PM EDT - 4 months ago

Xilio Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 2, 2026, 8:00 AM EST - 4 months ago

Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference

Feb 11, 2026, 9:34 PM EST - 5 months ago

Xilio Therapeutics Announces Pricing of Underwritten Offering

Jan 26, 2026, 7:00 AM EST - 5 months ago

Xilio Therapeutics Proxy statement: Proxy Filing

Jan 16, 2026, 7:00 AM EST - 6 months ago

Xilio Therapeutics Proxy statement: Proxy Filing

2026-01-08T13:50:16.000Z - 6 months ago

Xilio Therapeutics highlights upcoming milestones, corporate updates

Jan 8, 2026, 8:30 AM EST - 6 months ago

Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates

Nov 13, 2025, 4:00 PM EST - 8 months ago

Xilio Therapeutics Earnings release: Q3 2025

Nov 13, 2025, 4:00 PM EST - 8 months ago

Xilio Therapeutics Quarterly report: Q3 2025

2025-11-13T12:42:01.000Z - 8 months ago

Xilio Therapeutics expects cash to fund operations into Q1 of 2027

2025-11-13T12:35:19.000Z - 8 months ago

Xilio Therapeutics reports Q3 EPS (11c) vs (22c) last year

Nov 13, 2025, 7:30 AM EST - 8 months ago

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results

Nov 10, 2025, 4:30 PM EST - 8 months ago

Xilio Therapeutics Transcript: Status Update

Nov 10, 2025, 4:30 PM EST - 8 months ago

Xilio Therapeutics Press release: Status Update

Nov 10, 2025, 4:30 PM EST - 8 months ago

Xilio Therapeutics Slides: Status Update

2025-11-07T14:21:23.000Z - 8 months ago

Xilio Therapeutics presents new data across portfolio at SITC

2025-11-07T14:20:51.000Z - 8 months ago

Xilio Therapeutics announces new data on Phase 2 trial of vilastobart

Nov 7, 2025, 9:05 AM EST - 8 months ago

Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

Nov 7, 2025, 9:01 AM EST - 8 months ago

Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

Oct 30, 2025, 9:01 AM EDT - 8 months ago

Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting

Oct 20, 2025, 8:00 AM EDT - 9 months ago

Xilio Therapeutics Proxy statement: Proxy Filing

Oct 10, 2025, 8:00 AM EDT - 9 months ago

Xilio Therapeutics Proxy statement: Proxy Filing

Oct 3, 2025, 9:00 AM EDT - 9 months ago

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

2025-09-09T11:35:21.000Z - 10 months ago

Xilio Therapeutics announces initiation of Phase 2 trial for efarindodekin alfa

GILD

2025-09-09T11:35:08.000Z - 10 months ago

Xilio Therapeutics sees cash runway into 1Q27

Sep 9, 2025, 7:30 AM EDT - 10 months ago

Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead

2025-08-14T11:35:14.000Z - 11 months ago

Xilio Therapeutics reports Q2 EPS (16c) vs (24c) last year

Aug 14, 2025, 7:30 AM EDT - 11 months ago

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results

Aug 14, 2025, 7:30 AM EDT - 11 months ago

Xilio Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 7:30 AM EDT - 11 months ago

Xilio Therapeutics Earnings release: Q2 2025

2025-08-06T10:32:01.000Z - 11 months ago

Xilio Therapeutics initiated with an Outperform at Leerink

Jul 2, 2025, 4:30 PM EDT - 1 year ago

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 10, 2025, 4:30 PM EDT - 1 year ago

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors

Jun 5, 2025, 6:38 PM EDT - 1 year ago

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

Jun 5, 2025, 7:00 AM EDT - 1 year ago

Xilio Therapeutics Slides: Corporate Presentation

Jun 3, 2025, 8:00 AM EDT - 1 year ago

Xilio Therapeutics Proxy statement: Proxy Filing

2025-06-02T12:55:18.000Z - 1 year ago

Xilio Therapeutics announces pricing of $50M public offering

Jun 2, 2025, 8:46 AM EDT - 1 year ago

Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering

2025-06-02T10:20:44.000Z - 1 year ago

Xilio Therapeutics announces offering of warrants, no amount given

Jun 2, 2025, 6:11 AM EDT - 1 year ago

Xilio Therapeutics Announces Proposed Public Offering

May 31, 2025, 8:00 AM EDT - 1 year ago

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

May 8, 2025, 7:30 AM EDT - 1 year ago

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

May 7, 2025, 6:00 PM EDT - 1 year ago

Xilio Therapeutics Earnings release: Q1 2025

May 7, 2025, 6:00 PM EDT - 1 year ago

Xilio Therapeutics Quarterly report: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Xilio Therapeutics Registration statement: Registration Filing

May 2, 2025, 4:30 PM EDT - 1 year ago

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Xilio Therapeutics Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Xilio Therapeutics Proxy statement: Proxy Filing

Apr 23, 2025, 4:30 PM EDT - 1 year ago

Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Xilio Therapeutics Proxy statement: Proxy Filing

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Xilio Therapeutics Registration statement: Registration Filing

Mar 11, 2025, 7:30 AM EDT - 1 year ago

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Mar 11, 2025, 7:30 AM EDT - 1 year ago

Xilio Therapeutics Earnings release: Q4 2024

Mar 11, 2025, 7:30 AM EDT - 1 year ago

Xilio Therapeutics Annual report: Q4 2024

Mar 3, 2025, 9:50 AM EST - 1 year ago

Xilio Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 24, 2025, 4:30 PM EST - 1 year ago

Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Feb 12, 2025, 8:30 AM EST - 1 year ago

Xilio Therapeutics Transcript: Study Update

Feb 12, 2025, 8:30 AM EST - 1 year ago

Xilio Therapeutics Press release: Study Update

Feb 12, 2025, 8:30 AM EST - 1 year ago

Xilio Therapeutics Slides: Study Update

Feb 12, 2025, 7:35 AM EST - 1 year ago

Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

Feb 12, 2025, 7:33 AM EST - 1 year ago

AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

Jan 22, 2025, 8:30 AM EST - 1 year ago

Xilio Therapeutics Transcript: Study Update

Jan 22, 2025, 8:30 AM EST - 1 year ago

Xilio Therapeutics Press release: Study Update

Jan 21, 2025, 5:05 PM EST - 1 year ago

Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

Jan 17, 2025, 4:30 PM EST - 1 year ago

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 19, 2024, 7:30 AM EST - 1 year ago

Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI

Dec 16, 2024, 7:30 AM EST - 1 year ago

Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer

Nov 7, 2024, 4:30 PM EST - 1 year ago

Xilio Therapeutics Transcript: Study Update

Nov 7, 2024, 4:30 PM EST - 1 year ago

Xilio Therapeutics Press release: Study Update

Nov 7, 2024, 4:30 PM EST - 1 year ago

Xilio Therapeutics Slides: Study Update

Nov 7, 2024, 9:15 AM EST - 1 year ago

Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors

Nov 7, 2024, 9:05 AM EST - 1 year ago

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results

Nov 7, 2024, 9:00 AM EST - 1 year ago

Xilio Therapeutics Quarterly report: Q3 2024

Nov 7, 2024, 9:00 AM EST - 1 year ago

Xilio Therapeutics Earnings release: Q3 2024

Oct 30, 2024, 9:01 AM EDT - 1 year ago

Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Oct 4, 2024, 9:05 AM EDT - 1 year ago

Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Sep 4, 2024, 7:00 AM EDT - 1 year ago

Xilio Therapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 28, 2024, 4:01 PM EDT - 2 years ago

Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 8, 2024, 7:30 AM EDT - 2 years ago

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results

Aug 8, 2024, 7:30 AM EDT - 2 years ago

Xilio Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 7:30 AM EDT - 2 years ago

Xilio Therapeutics Earnings release: Q2 2024

Jun 13, 2024, 4:05 PM EDT - 2 years ago

Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D.

May 14, 2024, 7:30 AM EDT - 2 years ago

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results

May 14, 2024, 7:00 AM EDT - 2 years ago

Xilio Therapeutics Quarterly report: Q1 2024

May 14, 2024, 7:00 AM EDT - 2 years ago

Xilio Therapeutics Earnings release: Q1 2024

Apr 30, 2024, 8:00 AM EDT - 2 years ago

Xilio Therapeutics Registration statement: Registration Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Xilio Therapeutics Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Xilio Therapeutics Proxy statement: Proxy Filing

Apr 1, 2024, 4:05 PM EDT - 2 years ago

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results

Apr 1, 2024, 4:00 PM EDT - 2 years ago

Xilio Therapeutics Annual report: Q4 2023

Apr 1, 2024, 4:00 PM EDT - 2 years ago

Xilio Therapeutics Earnings release: Q4 2023

Mar 28, 2024, 7:05 AM EDT - 2 years ago

Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing

Mar 28, 2024, 7:00 AM EDT - 2 years ago

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

GILD

Mar 4, 2024, 10:30 AM EST - 2 years ago

Xilio Therapeutics Transcript: TD Cowen 44th Annual Health Care Conference 2024

Feb 28, 2024, 4:01 PM EST - 2 years ago

Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference

Feb 7, 2024, 12:30 PM EST - 2 years ago

Xilio Therapeutics Transcript: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Jan 31, 2024, 4:01 PM EST - 2 years ago

Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference

Jan 8, 2024, 7:30 AM EST - 2 years ago

Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies

Jan 8, 2024, 7:00 AM EST - 2 years ago

Xilio Therapeutics Slides: Corporate Presentation

Dec 7, 2023, 7:30 AM EST - 2 years ago

Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data

809trader Jul. 4 at 11:48 AM

0 · Reply

biohuntress Jun. 30 at 6:50 PM

2 · Reply

LabPsycho Jun. 30 at 6:03 PM

$XLO 1. Low float + 2. Trading at a fraction of cash! 3. Trading at an even smaller fraction of potentially more cash from partners later this year 4. Gilead, Abbvie, Roche partners

0 · Reply

LabPsycho Jun. 30 at 5:58 PM

$XLO Updated presentation out yesterday https://ir.xiliotx.com/static-files/0858e9cf-fd93-4938-8f02-396e622e8edf

1 · Reply

LabPsycho Jun. 30 at 2:54 PM

$XLO Look at the newcomers / posters below...looks like part of the PrePump gang moving in to help run this up to $19 or so soon?

2 · Reply

FutureScout Jun. 30 at 1:31 PM

1 · Reply

AlphaVisionn Jun. 30 at 1:30 PM

0 · Reply

809trader Jun. 30 at 12:50 PM

$XLO have a least 2 milestone that were supposed happen in the first half/second quarter. Today is the last day.

0 · Reply

TopSarge Jun. 29 at 6:12 PM

$XLO This one has momentum potential

1 · Reply

Jtlo Jun. 29 at 4:38 PM

$XLO come on 20

0 · Reply

LabPsycho Jun. 29 at 3:40 PM

$XLO @809trader Quite possibly, (without your help this time?) the $XLO melt up to $16 has begun?

1 · Reply

809trader Jun. 29 at 3:33 PM

$XLO 🤫🤫🤫🤫🤫🤫😎😎😎😎

0 · Reply

focafoca99 Jun. 29 at 11:44 AM

$XLO designated Ben Harshbarger as chief legal officer.

0 · Reply

biohuntress Jun. 26 at 10:35 PM

$XLO "Xilio is deploying its clinically validated masking technology to advance several highly differentiated bi- and multispecific molecules towards clinical development XTX501, Xilio’s PD1/masked IL-2 bispecific has the potential to be a foundational backbone therapy for combination regimens across a broad range of solid tumors, and the program is on track to advance into the clinic this year XTX601, Xilio’s masked CLDN18.2 T-cell engager and Xilio’s masked PSMA+STEAP1 dual-TAA targeted T-cell engager with co-stimulation both have first-in- class potential and further demonstrate the power of our masking technology to unlock the potential of T-cell engagers"

0 · Reply

AskSmacker Jun. 26 at 5:37 PM

$XLO competitors are showing promise, systemic tolerability remains an issue, and XTX501 is designed to address it

0 · Reply

biohuntress Jun. 25 at 7:44 PM

$XLO Vilastobart trial completed 6/16/26......are we gonna get a partner?...XTX 501 IND "mid 26"....hope we are basing here waiting for some news https://tinyurl.com/yfv7f9kj

3 · Reply

LabPsycho Jun. 23 at 1:59 PM

$XLO @809trader Now that's what I see as someone stepping up to the plate! The real game starts for me at $12.4 and above. Good luck

1 · Reply

AskSmacker Jun. 23 at 12:44 AM

$XLO "FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development" Should bode well for the upcomingIND submission. https://www.fda.gov/industry/fda-actions-accelerate-and-modernize-early-and-late-stage-clinical-development

1 · Reply

809trader Jun. 22 at 9:00 PM

$XLO I’m done with this games. Watch tomorrow!!!

1 · Reply

LabPsycho Jun. 22 at 2:28 PM

$XLO IMO, Based on today's paltry (again) volume it looks like if this thing ever trades 1 million or more shares in a day, it would go to either 3 or 22 on said hypothetical high volume trading day.

0 · Reply

LabPsycho Jun. 22 at 1:47 PM

$XLO @809trader Even a rounding error on that deal used towards XLO could 5X it.

0 · Reply

809trader Jun. 19 at 3:17 PM

$XLO can you please buy this puppy next: https://x.com/mroliverbarnes/status/2067976305631481867?s=46&t=wHopsM6AxwgEZIfi0ZU3Hg

0 · Reply

Market Cap	60.16M
Revenue (ttm)	43.77M
Net Income (ttm)	-35.04M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-80.05%
Debt to Equity Ratio	0.00

Volume	16,400
Avg Vol	46,522
Day's Range	N/A - N/A
Shares Out	6.58M
Stochastic %K	47%
Beta	-0.14
Analysts	Sell
Price Target	$20.00